Skip to main content
. 2016 Apr 28;11(4):e0152952. doi: 10.1371/journal.pone.0152952

Fig 1. HVTN 068 trial design with repeated immunogenicity measurements–cellular and antibody responses—during the 52 weeks of follow-up.

Fig 1